Next Article in Journal
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship
Next Article in Special Issue
Aquaporin-4 Expression during Toxic and Autoimmune Demyelination
Previous Article in Journal
Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases
Previous Article in Special Issue
Maternal Immune Activation Sensitizes Male Offspring Rats to Lipopolysaccharide-Induced Microglial Deficits Involving the Dysfunction of CD200–CD200R and CX3CL1–CX3CR1 Systems
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Does Siponimod Exert Direct Effects in the Central Nervous System?

Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, 18057 Rostock, Germany
Cells 2020, 9(8), 1771; https://doi.org/10.3390/cells9081771
Submission received: 1 July 2020 / Revised: 21 July 2020 / Accepted: 22 July 2020 / Published: 24 July 2020
(This article belongs to the Special Issue Glia Cells in Inflammation)

Abstract

The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes. Different sphingosine 1-phosphate receptor subtypes are expressed in the brain and spinal cord, and their pharmacological effects may improve disease development and neuropathology. Siponimod (BAF312) is a novel sphingosine 1-phosphate receptor modulator that has recently been approved for the treatment of active secondary progressive multiple sclerosis (MS). In this review article, we summarize recent evidence suggesting that the active role of siponimod in patients with progressive MS may be due to direct interaction with central nervous system cells. Additionally, we tried to summarize our current understanding of the function of siponimod and discuss the effects observed in the case of MS.
Keywords: sphingosine-1 phosphate; multiple sclerosis; inflammation; siponimod; astrocytes; demyelination; neuroprotection; astrocytes; microglia; fingolimod sphingosine-1 phosphate; multiple sclerosis; inflammation; siponimod; astrocytes; demyelination; neuroprotection; astrocytes; microglia; fingolimod

Share and Cite

MDPI and ACS Style

Kipp, M. Does Siponimod Exert Direct Effects in the Central Nervous System? Cells 2020, 9, 1771. https://doi.org/10.3390/cells9081771

AMA Style

Kipp M. Does Siponimod Exert Direct Effects in the Central Nervous System? Cells. 2020; 9(8):1771. https://doi.org/10.3390/cells9081771

Chicago/Turabian Style

Kipp, Markus. 2020. "Does Siponimod Exert Direct Effects in the Central Nervous System?" Cells 9, no. 8: 1771. https://doi.org/10.3390/cells9081771

APA Style

Kipp, M. (2020). Does Siponimod Exert Direct Effects in the Central Nervous System? Cells, 9(8), 1771. https://doi.org/10.3390/cells9081771

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop